Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Pipeline Promise | Explore VIR's diverse clinical development efforts in infectious diseases and oncology, with a focus on Hepatitis Delta Virus and solid tumor treatments |
Financial Fortress | Delve into VIR's robust cash reserves of $892.1 million, providing operational runway until mid-2027 despite challenges in revenue generation |
Market Challenges | Uncover the complexities of VIR's market performance, with stock trading near 52-week lows despite analyst projections of undervaluation |
Future Trajectories | Analyst price targets range from $15 to $31, reflecting varied outlooks on VIR's potential in Chronic Hepatitis Delta and emerging oncology programs |
Metrics to compare | VIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIRPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −1.2x | −0.5x | |
PEG Ratio | 0.11 | −0.05 | 0.00 | |
Price/Book | 0.7x | 1.7x | 2.6x | |
Price / LTM Sales | 36.3x | 8.4x | 3.3x | |
Upside (Analyst Target) | 210.6% | 284.3% | 38.7% | |
Fair Value Upside | Unlock | 18.7% | 5.2% | Unlock |